HALO
Halozyme Therapeutics, Inc. NASDAQ Listed Mar 16, 2004$65.20
Mkt Cap $7.7B
52w Low $47.50
51.0% of range
52w High $82.22
50d MA $65.83
200d MA $68.61
P/E (TTM)
24.2x
EV/EBITDA
8.8x
P/B
157.0x
Debt/Equity
0.0x
ROE
649.2%
P/FCF
12.5x
RSI (14)
—
ATR (14)
—
Beta
1.03
50d MA
$65.83
200d MA
$68.61
Avg Volume
1.8M
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
11388 Sorrento Valley Road · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | 2.15 | -0.24 | -111.2% | 80.48 | -3.5% | -9.0% | -10.5% | -11.8% | -12.2% | -12.6% | — |
| Nov 3, 2025 | AMC | 1.63 | 1.72 | +5.5% | 66.20 | +2.2% | +2.8% | +3.2% | +3.3% | +3.1% | +2.7% | — |
| Aug 5, 2025 | AMC | 1.23 | 1.54 | +25.2% | 60.81 | +3.7% | +2.5% | +2.1% | +3.4% | +3.4% | +5.3% | — |
| May 6, 2025 | AMC | 0.95 | 1.11 | +16.8% | 59.38 | +7.3% | +18.1% | +14.1% | +10.9% | +12.1% | -15.4% | — |
| Feb 18, 2025 | AMC | 1.17 | 1.26 | +7.7% | 57.90 | +1.9% | -0.2% | -0.8% | -0.3% | +1.0% | +0.2% | — |
| Oct 31, 2024 | AMC | 0.98 | 1.27 | +29.6% | 50.57 | +10.1% | +13.0% | +15.6% | +16.1% | +19.9% | +18.0% | — |
| Aug 6, 2024 | AMC | 0.76 | 0.91 | +19.7% | 51.94 | +7.8% | +4.2% | +4.9% | +6.3% | +8.0% | +7.8% | — |
| May 7, 2024 | AMC | 0.70 | 0.79 | +12.9% | 41.21 | +1.8% | +1.9% | +6.4% | +4.7% | +5.8% | +6.3% | — |
| Feb 20, 2024 | AMC | 0.83 | 0.82 | -1.2% | 36.00 | +4.8% | +6.6% | +10.3% | +12.7% | +10.2% | +10.7% | — |
| Nov 6, 2023 | AMC | 0.71 | 0.75 | +5.6% | 35.26 | +4.0% | +10.0% | +4.2% | +4.0% | +5.6% | +6.4% | — |
| Aug 8, 2023 | AMC | 0.63 | 0.74 | +17.5% | 43.31 | -2.1% | -1.6% | +1.7% | +1.0% | +1.3% | +1.6% | — |
| May 9, 2023 | AMC | 0.48 | 0.47 | -2.1% | 30.58 | +5.1% | +12.8% | +7.9% | +7.8% | +10.9% | +8.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19 | Benchmark | Maintains | Buy → Buy | — | $73.23 | $73.94 | +1.0% | -1.6% | -3.1% | -3.5% | -3.9% | -3.9% |
| Feb 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $73.23 | $73.94 | +1.0% | -1.6% | -3.1% | -3.5% | -3.9% | -3.9% |
| Jan 8 | TD Cowen | Maintains | Buy → Buy | — | $75.11 | $75.18 | +0.1% | -4.0% | -3.5% | -3.6% | -4.6% | -2.9% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.11 | $65.28 | +0.3% | +3.4% | +4.7% | +5.0% | +5.1% | +5.8% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $72.66 | $72.54 | -0.2% | -1.7% | -6.3% | -8.4% | -11.0% | -13.4% |
| Nov 18 | Goldman Sachs | Maintains | Neutral → Neutral | — | $70.56 | $70.08 | -0.7% | -0.7% | -0.4% | -2.3% | -0.3% | +4.9% |
| Nov 4 | Citizens | Maintains | Market Outperform → Market Outperform | — | $66.20 | $67.64 | +2.2% | +2.8% | +3.2% | +3.3% | +3.1% | +2.7% |
| Oct 27 | JP Morgan | Maintains | Neutral → Neutral | — | $66.15 | $66.80 | +1.0% | -0.5% | -1.1% | -1.3% | -2.3% | -1.5% |
| Oct 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $67.03 | $67.07 | +0.1% | -0.8% | -0.2% | -1.9% | -0.2% | -1.3% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.65 | $67.42 | +1.2% | -0.4% | +0.3% | +0.6% | -0.3% | +0.3% |
| Oct 14 | Leerink Partners | Upgrade | Underperform → Market Perform | — | $65.33 | $64.80 | -0.8% | +2.0% | +1.6% | +2.4% | +2.6% | +1.7% |
| Oct 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $74.94 | $74.98 | +0.1% | -4.3% | -8.0% | -10.6% | -11.9% | -13.0% |
| Sep 24 | Benchmark | Maintains | Buy → Buy | — | $77.57 | $77.93 | +0.5% | -2.5% | -4.6% | -4.9% | -5.5% | -5.5% |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $77.81 | $78.12 | +0.4% | +0.6% | -0.3% | -2.8% | -4.9% | -5.2% |
| Aug 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $67.27 | $68.19 | +1.4% | +2.5% | +4.0% | +5.7% | +6.5% | +6.8% |
| Aug 7 | JP Morgan | Maintains | Neutral → Neutral | — | $62.32 | $62.88 | +0.9% | -0.4% | +0.9% | +0.9% | +2.8% | +4.5% |
| Aug 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $60.81 | $63.05 | +3.7% | +2.5% | +2.1% | +3.4% | +3.4% | +5.3% |
| Aug 6 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $60.81 | $63.05 | +3.7% | +2.5% | +2.1% | +3.4% | +3.4% | +5.3% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.81 | $63.05 | +3.7% | +2.5% | +2.1% | +3.4% | +3.4% | +5.3% |
| Jul 16 | JP Morgan | Maintains | Neutral → Neutral | — | $56.60 | $57.09 | +0.9% | +2.5% | +2.1% | -0.3% | -1.2% | +1.7% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.43 | $54.69 | +0.5% | +0.6% | +3.0% | +2.2% | -2.1% | -1.1% |
| May 14 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $50.23 | $50.25 | +0.0% | -4.6% | -2.5% | +3.6% | +6.1% | +6.4% |
| May 13 | Leerink Partners | Downgrade | Market Perform → Underperform | — | $66.58 | $57.76 | -13.2% | -24.6% | -28.0% | -26.5% | -21.9% | -19.9% |
| May 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $59.38 | $63.69 | +7.3% | +18.1% | +14.1% | +10.9% | +12.1% | -15.4% |
| May 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $59.38 | $63.69 | +7.3% | +18.1% | +14.1% | +10.9% | +12.1% | -15.4% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.25 | $59.02 | -0.4% | +2.1% | +2.2% | +2.6% | +3.7% | +1.3% |
| Apr 21 | JP Morgan | Maintains | Neutral → Neutral | — | $58.79 | $58.74 | -0.1% | -2.6% | -1.0% | -0.6% | +0.8% | +2.9% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.53 | $59.21 | -0.5% | +1.0% | +2.4% | +3.2% | +3.2% | +2.3% |
| Feb 20 | Benchmark | Maintains | Buy → Buy | — | $57.77 | $57.35 | -0.7% | -0.6% | -0.0% | +1.3% | +0.4% | +0.3% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $57.90 | $58.98 | +1.9% | -0.2% | -0.8% | -0.3% | +1.0% | +0.2% |
| Feb 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.28 | $56.01 | -0.5% | +0.9% | +2.4% | +2.9% | +1.5% | +1.9% |
| Jan 13 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $52.80 | $52.65 | -0.3% | +2.5% | +2.0% | +3.2% | +4.9% | +3.8% |
| Jan 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $53.76 | $53.95 | +0.4% | -1.8% | +0.7% | +0.1% | +1.4% | +3.0% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.76 | $53.95 | +0.4% | -1.8% | +0.7% | +0.1% | +1.4% | +3.0% |
| Dec 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.13 | $48.65 | +1.1% | -0.3% | -0.7% | -0.2% | -0.8% | +4.9% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.60 | $48.66 | +0.1% | -3.6% | -2.6% | -3.4% | -3.0% | -2.2% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.00 | $49.51 | +1.0% | -2.5% | -2.5% | -1.1% | -1.6% | -0.8% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.81 | $44.57 | -0.5% | +2.1% | +2.0% | +9.4% | +6.7% | +6.7% |
| Nov 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $57.15 | $56.82 | -0.6% | +2.3% | +2.7% | +6.1% | +4.4% | +6.7% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.57 | $55.66 | +10.1% | +13.0% | +15.6% | +16.1% | +19.9% | +18.0% |
| Nov 1 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $50.57 | $55.66 | +10.1% | +13.0% | +15.6% | +16.1% | +19.9% | +18.0% |
| Oct 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.30 | $49.35 | +0.1% | -0.1% | +2.4% | +2.7% | +2.6% | +2.6% |
| Oct 7 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $59.18 | $57.92 | -2.1% | -9.0% | -8.5% | -14.4% | -11.9% | -10.4% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.43 | $60.56 | +0.2% | -2.1% | -10.9% | -10.4% | -16.2% | -13.7% |
| Sep 19 | JP Morgan | Downgrade | Overweight → Neutral | — | $62.31 | $62.48 | +0.3% | -4.5% | -4.9% | -6.1% | -9.8% | -10.3% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.30 | $62.78 | +0.8% | +1.0% | -0.6% | +0.0% | -4.5% | -4.9% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.54 | $61.02 | +0.8% | +2.9% | +3.9% | +2.3% | +2.9% | -1.7% |
| Aug 8 | Benchmark | Maintains | Buy → Buy | — | $54.12 | $54.26 | +0.3% | +0.6% | +2.0% | +3.6% | +3.5% | +6.1% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.12 | $54.26 | +0.3% | +0.6% | +2.0% | +3.6% | +3.5% | +6.1% |
| Aug 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $51.94 | $56.00 | +7.8% | +4.2% | +4.9% | +6.3% | +8.0% | +7.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Connaughton BernadetteDir | — | Sell | 1,625 | $63.48 | $103K | 38,498 | +0.73% | — |
8-K · 5.03
! Medium
Halozyme Therapeutics, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Halozyme Therapeutics shifted its fiscal year-end, which may affect timing of future earnings reports and investor comparisons with prior periods.
Apr 24
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Leadership transitions create uncertainty around strategic direction and operational continuity, potentially triggering stock volatility until investors assess the successor's qualifications and vision.
Apr 13
8-K
Unknown — 8-K Filing
Directors gain broad indemnification coverage for legal expenses and settlements, which may reduce accountability for questionable decisions and increase shareholder litigation risk and governance concerns.
Mar 26
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of an executive at Halo Collective (HALO) could signal leadership instability or strategic shifts, potentially impacting operational execution and investor confidence depending on the executive's role and replacement quality.
Mar 12
8-K
Halozyme Therapeutics, Inc. -- 8-K Filing
Halozyme's royalty revenue surged 52% to $868 million in 2025, with acquisitions of hyperconcentration technologies supporting robust 2026 guidance projecting 22-30% total revenue growth and 87-99% earnings-per-share expansion.
Feb 17
Data updated apr 25, 2026 12:55pm
· Source: massive.com